Additionally, p66ShcA overexpression promotes EMT in ErbB2-driven breast cancer cells, through up-regulated activation of the c-Met receptor by its ligand hepatocyte growth factor (HGF) [76]. Here, ERBB2 is linked to breast carcinoma.